Department of Radiology and Nuclear Medicine, University of Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
J Magn Reson Imaging. 2012 Mar;35(3):492-511. doi: 10.1002/jmri.22833.
The advent of gadolinium-based "hepatobiliary" contrast agents offers new opportunities for diagnostic magnetic resonance imaging (MRI) and has triggered great interest for innovative imaging approaches to the liver and bile ducts. In this review article we discuss the imaging properties of the two gadolinium-based hepatobiliary contrast agents currently available in the U.S., gadobenate dimeglumine and gadoxetic acid, as well as important pharmacokinetic differences that affect their diagnostic performance. We review potential applications, protocol optimization strategies, as well as diagnostic pitfalls. A variety of illustrative case examples will be used to demonstrate the role of these agents in detection and characterization of liver lesions as well as for imaging the biliary system. Changes in MR protocols geared toward optimizing workflow and imaging quality are also discussed. It is our aim that the information provided in this article will facilitate the optimal utilization of these agents and will stimulate the reader's pursuit of new applications for future benefit.
钆基“肝胆”对比剂的出现为诊断磁共振成像(MRI)提供了新的机会,并为肝脏和胆管的创新成像方法激发了极大的兴趣。在这篇综述文章中,我们讨论了目前在美国可用的两种基于钆的肝胆对比剂的成像特性,即钆贝葡胺和钆塞酸,以及影响其诊断性能的重要药代动力学差异。我们回顾了潜在的应用、方案优化策略以及诊断陷阱。将使用各种说明性病例示例来演示这些药物在检测和特征化肝脏病变以及成像胆道系统中的作用。还讨论了旨在优化工作流程和成像质量的磁共振方案的变化。我们的目标是,本文提供的信息将有助于优化这些药物的使用,并激发读者寻求新的应用,以造福未来。